Alzheimer’s disease (AD) is characterized by amyloid-beta (Aβ) deposits, which come in
myriad morphologies with varying clinical relevance. Previously, we observed an atypical Aβ …

The retina is a potential source of biomarkers for the detection of neurodegenerative
diseases. Accumulation of phosphorylated tau (p-tau) in the brain is a pathological feature …

The neuropathology of Alzheimer’s disease (AD) is characterized by hyperphosphorylated
tau neurofibrillary tangles (NFTs) and amyloid-beta (Aβ) plaques. Aβ plaques are …

Cognitive deficits in Alzheimer’s disease, specifically amnestic (memory dominant) deficits,
are associated with cholinergic degeneration in the basal forebrain. The cholinergic nucleus …

Background Advances in ultrasensitive detection of phosphorylated tau (p-tau) in plasma
has enabled the use of blood tests to measure Alzheimer’s disease (AD) biomarker changes. …

Alzheimer’s disease (AD) neuropathology is characterized by hyperphosphorylated tau
containing neurofibrillary tangles and amyloid-beta (Aβ) plaques. Normally these hallmarks are …

Background Posterior cortical atrophy is a rare syndrome characterised by early, prominent,
and progressive impairment in visuoperceptual and visuospatial processing. The disorder …

Background While most patients with Alzheimer’s disease (AD) present with memory
complaints, 30% of patients with early disease onset present with non-amnestic symptoms. This …

Using 7T T2 ⁎ -weighted imaging, we scanned post-mortem hemispheres of Alzheimer
patients and age-matched controls to describe the patterns of appearance of cortical lamination …

Alzheimer’s disease is characterized by cortical atrophy on MRI and abnormal depositions
of amyloid-beta, phosphorylated-tau and inflammation pathologically. However, the relative …